Attendees have the opportunity to review the basic, fundamental principles of amyloid PET imaging, including radiochemistry of amyloid agents, radio-tracer synthesis, PET acquisition and data processing, including application of corrections for the partial volume effect and co-registration with structural data.
The concept of amyloid positive will be extensively discussed, and the attendees should be able to characterize the advantages and disadvantages of both dichotomized and continuous variable approaches to amyloid PET analyses with respect to specific purposes or intended uses of the outcome.
Attendees will have the opportunity to evaluate amyloid PET data in specific clinical and clinical research contexts, including review of typical findings in Alzheimer’s disease dementia, mild cognitive impairment due to Alzheimer’s disease, and in clinically normal individuals. These phenomena will also be related to familial forms of the disease and to non-AD processes such as fronto-temporal lobar degeneration and dementia with Lewy bodies.
Particular attention will be given to the assessment of longitudinal amyloid PET data as it relates to methods of analysis and comparison to other domains of data, including structural and functional brain imaging data, and clinical and cognitive outcomes.